In Brief: NABI
Executive Summary
NABI: Company formerly known as North American Biologicals privately places $70 mil. principal amount of 6-1/2% convertible subordinated notes due 2003, Boca Raton, Fla.-based NABI announces Feb. 7. Robertson, Stephens and Raymond James, the notes' initial purchasers, have an option for 30 days to buy up to an additional $10.5 mil. principal amount of notes solely to cover over-allotments, if there are any, NABI notes. The notes are convertible to common stock at $14 per share any time after April 8. NABI says it will use the notes to repay high interest bank indebtedness and for general corporate purposes; there will be a first quarter charge to earnings of $1 mil. related to the early extinguishment of this indebtedness, the company adds...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth